Molecular structure of Bcl-2 Inhibitor II, YC137, CAS Number: 810659-53-1
Bcl-2 Inhibitor II, YC137 (CAS 810659-53-1)
See product citations (1)
Application:
Bcl-2 Inhibitor II, YC137 is a naphthoquinone inducer of apoptosis
CAS Number:
810659-53-1
Molecular Weight:
511.6
Molecular Formula:
C24H21N3O6S2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Bcl-2 Inhibitor II, YC137 is a cell-permeable naphthoquinone compound that selectively induces apoptosis of Bcl-2-overexpressing cells (< 300 nM in MDA-MB435B breast cancer cells) with little effect on a variety of primary cells. Bcl-2 Inhibitor II, YC137 preferentially binds Bcl-2 (Ki = 1.3 muM) and disrupts its interaction with Bid BH3, thereby blocking the anti-apoptotic activity of Bcl-2. This has shown to induce the release of cytochrome c from mitochondria as well as activate caspase-9.
Bcl-2 Inhibitor II, YC137 (CAS 810659-53-1) References
- Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2. | Real, PJ., et al. 2004. Cancer Res. 64: 7947-53. PMID: 15520201
- Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1. | Xing, C., et al. 2007. Bioorg Med Chem. 15: 2167-76. PMID: 17227711
- Mechanistic analysis of resistance to REIC/Dkk-3-induced apoptosis in human bladder cancer cells. | Kobayashi, T., et al. 2008. Acta Med Okayama. 62: 393-401. PMID: 19122685
- JNK is constitutively active in mantle cell lymphoma: cell cycle deregulation and polyploidy by JNK inhibitor SP600125. | Wang, M., et al. 2009. J Pathol. 218: 95-103. PMID: 19206150
- Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization. | Buron, N., et al. 2010. PLoS One. 5: e9924. PMID: 20360986
- Acquired resistance to miriplatin in rat hepatoma AH109A/MP10 is associated with increased Bcl-2 expression, leading to defects in inducing apoptosis. | Hanada, M., et al. 2010. Oncol Rep. 24: 1011-8. PMID: 20811683
- Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21). | Drakos, E., et al. 2011. Leukemia. 25: 856-67. PMID: 21394100
- Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells. | Low, SY., et al. 2012. Cancer Lett. 314: 166-75. PMID: 22033244
- Induction of Bcl-2 expression by hepatitis B virus pre-S2 mutant large surface protein resistance to 5-fluorouracil treatment in Huh-7 cells. | Hung, JH., et al. 2011. PLoS One. 6: e28977. PMID: 22216150
- Bcl-2 and Bcl-xL suppress glucose signaling in pancreatic β-cells. | Luciani, DS., et al. 2013. Diabetes. 62: 170-82. PMID: 22933114
- Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line. | Nishi, R., et al. 2013. Cancer Sci. 104: 502-7. PMID: 23320492
- Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes. | Fandy, TE., et al. 2014. Clin Cancer Res. 20: 1249-58. PMID: 24423613
- BHRF1 exerts an antiapoptotic effect and cell cycle arrest via Bcl-2 in murine hybridomas. | Milián, E., et al. 2015. J Biotechnol. 209: 58-67. PMID: 26057602
Inhibitor of:
Bcl-2.Activator of:
caspase-9.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Bcl-2 Inhibitor II, YC137, 5 mg | sc-221287 | 5 mg | $204.00 |